FDA criticizes Lundbeck for now-deleted webpages promoting its migraine treatment

FDA hits Lundbeck with untitled letter over efficacy claims on migraine drug Vyepti

Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy clai | The FDA took issue…